A novel sialyl Le(X) expression score as a potential prognostic tool in colorectal cancer - PubMed (original) (raw)

A novel sialyl Le(X) expression score as a potential prognostic tool in colorectal cancer

Leif Schiffmann et al. World J Surg Oncol. 2012.

Abstract

Background: Treatment decisions in colorectal cancer subsequent to surgery are based mainly on the TNM system. There is a need to establish novel prognostic markers based on the molecular characterization of tumor cells. Evidence exists that sialyl Le(X) expression is correlated with an unfavorable outcome in colorectal cancer. The aim of this study was to establish a simple sialyl Le(X) staining score and to determine a potential correlation with the prognosis in a series of advanced colorectal carcinoma patients.

Methods: In order to implement routine use of sialyl Le(X) immunohistology, we established a new, easily reproducible score and defined a cutoff which discriminated groups with better or worse outcome, respectively. We then correlated sialyl Le(X) expression of 215 UICC stage III and IV patients with disease-free and cancer-related survival.

Results: A five-stage score could be established based on automated immunohistochemical stainings. Using a statistical model, we calculated a cutoff to discriminate between weak and strong staining positivity of sialyl Le(X). Patients with strong positive specimens had a worse cancer-related survival (P = 0.004) but no difference was observed for disease-free survival (P = 0.352).

Conclusions: These results demonstrate a strong correlation between high sialyl Le(X)-expression in colorectal carcinomas and cancer-related survival. Our highly standardized and easy-to-use staining score is suitable for routine use and hence it could be recommended to evaluate sialyl Le(X)-expression as part of the standard histopathological analysis of colorectal carcinomas and to validate the score prospectively based on a larger population.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Showcase the image sections of the five typical immunohistochemical staining patterns of sialyl Le X (100x magnification).

Figure 2

Figure 2

Martingale residuals as a function of the sialyl Le X staining score. Each dot represents the difference between the observed individual status and the calculated cumulative risk at the end of the observation period.

Figure 3

Figure 3

Cancer-related survival after resection of colorectal cancer depending on sialyl Le X expression stages III and IV (A), stage III alone (B) and stage IV alone (C).

Similar articles

Cited by

References

    1. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. and Robert Koch-Institut, Krebs in Deutschland - Häufigkeiten und Trends. 5. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V, Saarbrücken; 2006. p. p108.
    1. Staib L, Link KH, Blatz A, Beger HG. Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients – a monoinstitutional experience. World J Surg. 2002;26:59–66. doi: 10.1007/s00268-001-0182-5. - DOI - PubMed
    1. Davis NC, Evans EB, Cohen JR, Theile DE, Job DM. Colorectal cancer: a large unselected Australian series. Aust N Z J Surg. 1987;57:153–159. doi: 10.1111/j.1445-2197.1987.tb01326.x. - DOI - PubMed
    1. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704–1719. doi: 10.1038/sj.bjc.6605061. - DOI - PMC - PubMed
    1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. NEJM. 2005;352:476–487. doi: 10.1056/NEJMra040958. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources